Abstract
Androgenic alopecia (AGA) is the most common alopecia that is heritable, androgen-dependent and occurs in both sexes with defined patterns such as Male pattern hair loss in men and Female pattern hair loss in women. AGA affects at least 50 % of men by the age of 50 years, and up to 70 % of all males in later life. The aim.The research was aimed to substantiate the optimal concentration of excipients and active pharmaceutical ingredients (APIs) of the emulgel intended for the topical treatment of androgenic alopecia. Materials and methods. In this study the samples of the emulgel bases containing different carbomer Ultrez10 concentrationsin the range of 0.3–0.6 % and its neutralizers (0.1 % of potassium sorbate and 0 % or 0.2 % of triethanolamine) were used. Colloidal and thermal stability, pH, rheological properties (structural viscosity, mechanical stability, degree of thixotropy) of these samples were determined. The emulgel samples with different percentages of the Serenoa repens dry extract and the Sophora japonica tincture were used in the biopharmaceutical studies. The samples of the emulgel with the antioxidant butylhydroxytoluene different concentrations (0 %, 0.01 %, 0.02 %, 0.03 %) were used to determine acid value during 1 year of the emulgel storage. Results and discussion. It was experimentally substantiated the optimal ratio of the emulgel ingredients that provide good APIs release and necessary consumer properties of the semi-solid remedy like application compliance, safety and storage stability. Conclusions. Physicochemical, rheological and biopharmaceutical properties of emulgel bases have been studied. It was found that the base №2 (in which the concentrations of Carbomer Ultraz 10, potassium sorbate and triethanolamine are 0.3 %, 0.1 %, 0.2 % respectively) possessed the optimal properties. Considering the results of the complete range of experimental research it was developed the final formulation of the emulgel intended for AGA treatment which included the concentration of the APIs, neutralizers, preservatives, antioxidant and fragrance.
Highlights
Skin diseases and pathological conditions significantly affect human psycho-emotional health and quality of life [1, 2]
This research was aimed to substantiate the optimal concentration of the excipients and the active pharmaceutical ingredients (APIs) of the emulgel intended for the topical androgenic alopecia (AGA) treatment
Samples of the emulgel with the different APIs concentrations used for the biopharmaceutical studying: – 6 samples of the emulgel containing the Serenoa repens dry extract (SRDE) in the range of 1–6 % with 1 % increments; – 5 samples of the emulgel containing the Sophora japonica tincture (SJT) different concentrations, namely 3 %, 5 %, 7 %, 10 %, 12 %. 3
Summary
Skin diseases and pathological conditions significantly affect human psycho-emotional health and quality of life [1, 2]. Excessive hair loss or alopecia is one of the most common dermatological pathologies. AGA is the most common alopecia that is heritable, androgen-dependent and occurs in both sexes with defined patterns such as Male pattern hair loss (MPHL) in men and Female pattern hair (2020), «EUREKA: Health Sciences» Number 5 loss (FPHL)in women. AGA affects at least 50 % of men by the age of 50 years, and up to 70 % of all males in later life. AGA becomes a medical problem when the hair loss is excessive, premature and stressful to the patients, especially for women and young men [5]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
